Checklist:
- Rare disease and the reality of Duchenne muscular dystrophy
- Patient choice, risk, and the Right to Try idea
- The FDA commissioner’s role in access and urgency
- Accelerated approval and the cost of waiting
- Listening to patients, doctors, and rare-disease experts
I just turned 25, and for people living with Duchenne muscular dystrophy, that is not a small thing. It is a milestone wrapped in fear, because this disease keeps taking pieces of a life long before most people ever have to think about them. Sleep gets harder, movement gets harder, and ordinary tasks turn into a grind.
That is the part Washington tends to miss. To a healthy policymaker, a treatment decision can sound like a line on a spreadsheet, but to a patient with a terminal illness, it can mean the difference between another year of strength and another year slipping away. Time is not abstract when your body is the one paying the bill.
For people in that position, the real question is not whether science matters. Science matters a great deal, and no one living with a serious illness wants reckless medicine dressed up as hope. The question is who gets to weigh the risk when the patient, the doctor, and the evidence all point in the same direction.
That is why the debate over the next FDA commissioner matters so much. For most Americans, the job is a blur of acronyms and hearings, but for families facing rare diseases, it can shape access, delay, and the number of options that are still left on the table. One regulator can have an outsize impact on how long people get to keep fighting.
The Right to Try Act was important because it pushed back against the old habit of treating very sick patients like spectators in their own care. When approved options are gone and a physician believes an investigational treatment might help, the patient should not be shoved aside by a system that values caution over urgency every time. Partnership should beat paternalism.
That idea should not stop at one law. It should shape the culture of the FDA more broadly, especially for rare diseases and individualized treatments that do not fit neatly into a standard approval box. The people facing those choices are not asking for miracles on demand. They are asking for a fair shot before the window closes.
The agency already understands that delay can be deadly, which is exactly why accelerated approval exists. A slower timeline can sound responsible in a hearing room, but for someone losing strength month by month, it can feel like a sentence. The FDA has used that pathway before, and that flexibility matters when every season can bring a new loss.
Living with Duchenne also exposes the gap between policy and reality. Even when a treatment exists, actually getting to it can mean long travel, repeated appointments, and years of uncertainty that healthy people rarely imagine. What sounds manageable in theory can become brutal when the body is fighting back every step of the way.
That is why the next commissioner should listen to patients, not just institutions. Rare-disease families know the stakes in a way no briefing memo can capture, and they deserve a seat in the conversation about access, safety, and speed. Regulators can still demand evidence without ignoring urgency.
There is also a case for bringing people with real biotech experience into the leadership mix, especially those who have spent years building treatments instead of just policing them from a distance. The FDA needs people who understand both the science and the human cost of waiting. That kind of perspective can make the difference between a rigid agency and one that actually serves the people it regulates.
For a patient with Duchenne, hope is not a slogan. It is the chance to keep working, to build a future, to fall in love, to get married, to live long enough for birthdays to feel normal instead of borrowed. The fight is not for fantasy, but for enough room to keep going.
That is why Senate leaders face a real test when they weigh the next FDA commissioner. They can choose someone who sees patients as partners and treats rare disease like an urgent human problem, or they can keep rewarding a system that moves too slowly for the people it claims to protect. The difference shows up in days, months, and years that cannot be replaced.
People living with Duchenne do not need anyone to promise forever. They need a system that stops acting like time is unlimited, because for them it never has been. Every decision about access lands with force, and the nation should be hearing that before another chance slips away.
